330
Participants
Start Date
June 30, 2003
Primary Completion Date
August 31, 2007
Study Completion Date
December 31, 2007
Insulin like growth factor, type 1
0.05 mg per kg body weight given subcutaneously twice daily
Placebo
The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
Beth Israel Medical Center, New York
University of Rochester Medical Center, Rochester
University of Pennsylvania, Pennsylvania Hospital, Philadelphia
West Virginia University, Morgantown
Emory University, Atlanta
Mayo Clinic in Jacksonville, Jacksonville
University of Mississippi, Jackson
Ohio State University, Columbus
Cleveland Clinic, Cleveland
University of Cincinnati, Cincinnati
Indiana University, Indianapolis
University of Michigan Medical Center, Ann Arbor
Henry Ford Hospital, Detroit
Froedtert and Medical College Clinics, Milwaukee
Hennepin County Medical Center, Minneapolis
Mayo Clinic, Rochester
Methodist Hospital, Houston
Mayo Clinic in Scottsdale, Scottsdale
California Pacific Medical Center, San Francisco
University of Puerto Rico, San Juan
Lead Sponsor
Collaborators (1)
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
ALS Association
OTHER
Cephalon
INDUSTRY
Mayo Clinic
OTHER